Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Guillaume Charpentier, MD"'
Autor:
Dulanjalee Kariyawasam, MD, Carole Morin, MD, Kristina Casteels, ProfMD, Claire Le Tallec, MD, Annie Sfez, MD, Cécile Godot, MD, Erik Huneker, MSc, Nathalie Garrec, MD, Pierre-Yves Benhamou, ProfMD, Michel Polak, ProfMD, Guillaume Charpentier, MD, Sylvia Franc, MD, Jacques Beltrand, ProfMD
Publikováno v:
The Lancet: Digital Health, Vol 4, Iss 3, Pp e158-e168 (2022)
Summary: Background: Time in range (TIR) goals are rarely met in children with type 1 diabetes, except at the cost of increased hypoglycaemia episodes. Our objective was to evaluate the safety and efficiency of the Diabeloop DBL4K (Diabeloop, Grenobl
Externí odkaz:
https://doaj.org/article/61c960e03c0742cbbfa664fac8d4afc7
Autor:
Pierre-Yves Benhamou, ProfMD, Sylvia Franc, MD, Yves Reznik, ProfMD, Charles Thivolet, ProfMD, Pauline Schaepelynck, MD, Eric Renard, ProfMD, Bruno Guerci, ProfMD, Lucy Chaillous, MD, Celine Lukas-Croisier, MD, Nathalie Jeandidier, ProfMD, Helene Hanaire, ProfMD, Sophie Borot, MD, Maeva Doron, Pierre Jallon, Ilham Xhaard, PhD, Vincent Melki, MD, Laurent Meyer, MD, Brigitte Delemer, ProfMD, Marie Guillouche, MD, Laurene Schoumacker-Ley, MD, Anne Farret, MD, Denis Raccah, ProfMD, Sandrine Lablanche, MD, Michael Joubert, ProfMD, Alfred Penfornis, ProfMD, Guillaume Charpentier, MD
Publikováno v:
The Lancet: Digital Health, Vol 1, Iss 1, Pp e17-e25 (2019)
Summary: Background: Closed-loop insulin delivery systems are expected to become a standard treatment for patients with type 1 diabetes. We aimed to assess whether the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system impro
Externí odkaz:
https://doaj.org/article/bf42d9c4d29145c98bb3dcf6ec9f667f